Ovid Therapeutics (OVID) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.6M

Revenue (quarter)

$733,000.00

Revenue growth (year over year)

−88.31%

Gross profit (trailing twelve months)

$1.6M

Gross margin

100.00%

Net income (trailing twelve months)

−$34.5M

Net income (quarter)

−$15.0M

Net income growth (year over year)

−220.43%

Net margin

−2178.84%

Return on equity

−25.96%

EPS (trailing twelve months)

−$0.21

Book value per share

$1.14

P/E (trailing twelve months)

—

Price to book

2.10

Debt to assets

9.52%

Payout ratio

—

Dividend yield

—

Company profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

• Is Ovid Therapeutics (OVID) profitable?

  No. Ovid Therapeutics reported a net loss of $34.5M over the trailing twelve months.

• How much revenue does Ovid Therapeutics (OVID) make?

  Ovid Therapeutics generated $1.6M in revenue over the trailing twelve months, down 88.31% year over year.

• How do I buy stock in Ovid Therapeutics (OVID)?

  OVID trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.